Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • David Erlinge
  • Akiko Maehara
  • Ori Ben-Yehuda
  • Hans Erik Bøtker
  • Michael Maeng
  • Lars Kjøller-Hansen
  • Engstrøm, Thomas
  • Mitsuaki Matsumura
  • Aaron Crowley
  • Ovidiu Dressler
  • Gary S. Mintz
  • Ole Fröbert
  • Jonas Persson
  • Rune Wiseth
  • Alf Inge Larsen
  • Lisette Okkels Jensen
  • Jan Erik Nordrehaug
  • Øyvind Bleie
  • Elmir Omerovic
  • Claes Held
  • Stefan K. James
  • Ziad A. Ali
  • James E. Muller
  • Gregg W. Stone
  • Ole Ahlehoff
  • Azad Amin
  • Oskar Angerås
  • Praveen Appikonda
  • Saranya Balachandran
  • Ståle Barvik
  • Kristoffer Bendix
  • Maria Bertilsson
  • Ulrika Boden
  • Nigussie Bogale
  • Vernon Bonarjee
  • Fredrik Calais
  • Jörg Carlsson
  • Steen Carstensen
  • Christina Christersson
  • Evald Høj Christiansen
  • Maria Corral
  • De Backer, Ole
  • Steffen Helqvist
  • Holmvang, Lene
  • Allan Iversen
  • Erik Jørgensen
  • Henning Kelbæk
  • Jacob Lønborg
  • Rikke Sørensen
  • Anne Thuesen
  • PROSPECT II Investigators

Background: Near-infrared spectroscopy (NIRS) and intravascular ultrasound are promising imaging modalities to identify non-obstructive plaques likely to cause coronary-related events. We aimed to assess whether combined NIRS and intravascular ultrasound can identify high-risk plaques and patients that are at risk for future major adverse cardiac events (MACEs). Methods: PROSPECT II is an investigator-sponsored, multicentre, prospective natural history study done at 14 university hospitals and two community hospitals in Denmark, Norway, and Sweden. We recruited patients of any age with recent (within past 4 weeks) myocardial infarction. After treatment of all flow-limiting coronary lesions, three-vessel imaging was done with a combined NIRS and intravascular ultrasound catheter. Untreated lesions (also known as non-culprit lesions) were identified by intravascular ultrasound and their lipid content was assessed by NIRS. The primary outcome was the covariate-adjusted rate of MACEs (the composite of cardiac death, myocardial infarction, unstable angina, or progressive angina) arising from untreated non-culprit lesions during follow-up. The relations between plaques with high lipid content, large plaque burden, and small lumen areas and patient-level and lesion-level events were determined. This trial is registered with ClinicalTrials.gov, NCT02171065. Findings: Between June 10, 2014, and Dec 20, 2017, 3629 non-culprit lesions were characterised in 898 patients (153 [17%] women, 745 [83%] men; median age 63 [IQR 55–70] years). Median follow-up was 3·7 (IQR 3·0–4·4) years. Adverse events within 4 years occurred in 112 (13·2%, 95% CI 11·0–15·6) of 898 patients, with 66 (8·0%, 95% CI 6·2–10·0) arising from 78 untreated non-culprit lesions (mean baseline angiographic diameter stenosis 46·9% [SD 15·9]). Highly lipidic lesions (851 [24%] of 3500 lesions, present in 520 [59%] of 884 patients) were an independent predictor of patient-level non-culprit lesion-related MACEs (adjusted odds ratio 2·27, 95% CI 1·25–4·13) and non-culprit lesion-specific MACEs (7·83, 4·12–14·89). Large plaque burden (787 [22%] of 3629 lesions, present in 530 [59%] of 898 patients) was also an independent predictor of non-culprit lesion-related MACEs. Lesions with both large plaque burden by intravascular ultrasound and large lipid-rich cores by NIRS had a 4-year non-culprit lesion-related MACE rate of 7·0% (95% CI 4·0–10·0). Patients in whom one or more such lesions were identified had a 4-year non-culprit lesion-related MACE rate of 13·2% (95% CI 9·4–17·6). Interpretation: Combined NIRS and intravascular ultrasound detects angiographically non-obstructive lesions with a high lipid content and large plaque burden that are at increased risk for future adverse cardiac outcomes. Funding: Abbott Vascular, Infraredx, and The Medicines Company.

OriginalsprogEngelsk
TidsskriftThe Lancet
Vol/bind397
Udgave nummer10278
Sider (fra-til)985-995
Antal sider11
ISSN0140-6736
DOI
StatusUdgivet - 13 mar. 2021

Bibliografisk note

Publisher Copyright:
© 2021 Elsevier Ltd

ID: 302199823